Jolt Capital, a French private equity firm that pumps in growth investment in European deeptech companies has invested €24 million in BioSerenity, a French medtech startup. The company developes solutions dedicated to personallsed patient continuous care and is known for itsinnovative medical services in electrophysiology.
This investment will enable BioSerenity to accelerate the international development of its activities by building on its two main markets – France and the United States, and focusing on Europe. The funding will also be used to deploy even more powerful AI to help doctors with their diagnoses. It will also strengthen its management team drive further development.
Related: Pantheon Vision launches with $2.5m to develop bioengineered corneal implants
Founded in 2014 by Pierre-Yves Frouin, BioSerenity develops medical devices to help diagnose and monitor patients with chronic diseases such as epilepsy. The medical devices are composed of medical sensors, smart clothing, a smartphone app, a web platform to perform data analysis through Medical AI for detection of digital biomarkers.
The company initially focused on Neurology has now extended the scope of its innovative solutions to other fields, including sleep disorders and cardiology. Today, with more than 300 partners and 150,000 patients treated each year, BioSerenity is among the leaders in neurological diagnostics and sleep disorders.
Jean Schmitt, Managing Partner and Chairman of Jolt Capital, commented: “Healthcare is one of the strategic sectors that needs to benefit from an acceleration in funding if we are to see French medical and industrial leadership emerge. This is why we are delighted to invest in BioSerenity, which has created the best medical devices and AI software on the market for electroencephalography. BioSerenity is a perfect example of Jolt Capital’s investment thesis. When a company has a proprietary base of market-proven, cutting-edge technologies, its ability to attract significant financing to support its development remains intact”.
“As we enter the next phase of our development, we are delighted to benefit from Jolt Capital’s recapitalisation following the recent growth crisis,” commented Pierre-Yves Frouin, Founder, and Samir Medjebar, General Manager Services in France. “In less than 10 years, our technology has helped more than a million patients and we have spearheaded innovation in the fields of ambulatory neurology, sleep and medical AI. This next step will allow us to bring our technology to more patients and continue to innovate.”
Vincent Marcel has been appointed CEO of the company: “I am impressed by the unique combination of disruptive technologies that BioSerenity has developed in the field of neurology and innovative patient care services. I look forward to leading the next stage of development, leaning on my experience in healthcare services and the strong commitment of Jolt Capital. Together with the BioSerenity teams, we will accelerate in Europe and the United States to bring personalised, preventive and cost-effective medicine for neurological and sleep disorders.”
